About Dopavision
Dopavision is a company based in Berlin (Germany) founded in 2017. Dopavision has raised $15.54 million across 3 funding rounds from investors including Novartis, BMBF and Ababax. Dopavision offers products and services including MyopiaX®. Dopavision operates in a competitive market with competitors including Bausch & Lomb, Appasamy Associates, Katalyst Surgical, Lamellar and Moria Surgical, among others.
- Headquarter Berlin, Germany
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.54 M (USD)
in 3 rounds
-
Latest Funding Round
$14.19 M (USD), Series A
Jul 14, 2021
-
Investors
Novartis
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dopavision
Dopavision offers a comprehensive portfolio of products and services, including MyopiaX®.
Light-based therapy to slow myopia progression in children via apps.
People of Dopavision
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Dopavision
Dopavision has successfully raised a total of $15.54M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14.19 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dopavision
Dopavision has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Novartis, BMBF and Ababax.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Locked | Locked | Locked | |
|
Flying Health is recognized as a leading ecosystem for digital and sustainable healthcare solutions.
|
Locked | Locked | Locked |
Investor details for Dopavision
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dopavision
Investment portfolio details for Dopavision
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dopavision
Detailed financials for Dopavision
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dopavision Comparisons
Peer comparison for Dopavision
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dopavision
Dopavision operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bausch & Lomb, Appasamy Associates, Katalyst Surgical, Lamellar and Moria Surgical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals and instruments are developed for eye care.
|
|
| Locked | Locked | Locked |
Ophthalmic instruments and pharmaceutical products are developed for eye care.
|
|
| Locked | Locked | Locked |
Titanium ophthalmic surgical instruments are manufactured and repaired.
|
|
| Locked | Locked | Locked |
Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies
|
|
| Locked | Locked | Locked |
Precision instruments for eye surgery are designed and manufactured.
|
Detailed competitors of Dopavision
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dopavision
Complete news archive for Dopavision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dopavision
Dopavision was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Dopavision is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Dopavision is a funded company, having raised a total of $15.54M across 3 funding rounds to date.
Dopavision was founded in 2017 in Berlin, Germany, within the health technology sector. Digital therapeutics for myopia are created by the company, focusing on light stimulation delivered to photosensitive retinal cells. Dopamine modulation is facilitated to regulate eye growth. A mobile application named Myopiax is provided for children, integrating treatment with engaging activities. Operations center on addressing pediatric vision issues through non-invasive methods.
Dopavision's top competitors include Bausch & Lomb, Appasamy Associates and Katalyst Surgical.
Dopavision offers MyopiaX®.
Dopavision has 7 investors. Key investors include Novartis, BMBF, Ababax, Seventure Partners, and Boehringer Ingelheim Venture Fund.